跳转至内容
Merck
CN

SML4170

Desthiobiotin-iodoacetamide

≥98% (HPLC), powder, pan-cysteine profiling tag

别名:

(4R,5S)-N-[2-[(2-Iodoacetyl)amino]ethyl]-5-methyl-2-oxo-4-imidazolidinehexanamide, DBIA, Desthiobiotin-IAA,Iodoacetamide-desthiobiotin

登录 查看组织和合同定价。

选择尺寸


关于此项目

经验公式(希尔记法):
C14H25IN4O3
化学文摘社编号:
分子量:
424.28
NACRES:
NA.21
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助
技术服务
需要帮助?我们经验丰富的科学家团队随时乐意为您服务。
让我们为您提供帮助

SMILES string

ICC(NCCNC(CCCCC[C@H]1NC(N[C@H]1C)=O)=O)=O

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

Quality Level

Application

Desthiobiotin-iodoacetamide may be incorporated into the design of nanomaterials for applications in biosensing and imaging due to its chemical properties. It may also be used as a probe for cysteine-reactive affinity labeling in chemoproteomics, enabling the study of protein interactions and modifications.

Biochem/physiol Actions

The desthiobiotin-iodoacetamide (DBIA) probe represents a significant advancement in cysteine-reactive affinity labeling, surpassing alkyne-iodoacetamide in enrichment efficacy and mass spectrometry compatibility. With the ability to profile over 8,000 ligandable cysteine sites within 3 hours at 0.5-1 mM concentration, DBIA offers unparalleled proteome coverage and efficiency. Its unique feature of quantitative release from avidin under mild acidic conditions in organic solvents enhances its versatility in proteomic analyses. DBIA′s applicability to live cell cultures further expands its utility, positioning it as a powerful tool for investigating cysteine reactivity and protein dynamics in physiologically relevant contexts.

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本?

如果您需要特殊版本,可通过批号或批次号查找具体证书。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Lisa M Boatner et al.
Cell chemical biology, 30(6), 683-698 (2023-04-30)
Cysteine chemoproteomics provides proteome-wide portraits of the ligandability or potential "druggability" for thousands of cysteine residues. Consequently, these studies are facilitating resources for closing the druggability gap, namely, achieving pharmacological manipulation of ∼96% of the human proteome that remains untargeted
Mariko Takahashi et al.
Cell, 187(10), 2536-2556 (2024-04-24)
Cysteine-focused chemical proteomic platforms have accelerated the clinical development of covalent inhibitors for a wide range of targets in cancer. However, how different oncogenic contexts influence cysteine targeting remains unknown. To address this question, we have developed "DrugMap," an atlas
Yi Chen et al.
Journal of inorganic biochemistry, 254, 112518-112518 (2024-03-10)
Cisplatin is widely used as anticancer drugs, and DNA is considered as the main target. Considering its high affinity towards cysteines and the important role of cystine containing proteins, we applied a competitive activity-based protein profiling strategy to identify protein
Tom Kamperman et al.
Nature communications, 10(1), 4347-4347 (2019-09-27)
Spatiotemporal control over engineered tissues is highly desirable for various biomedical applications as it emulates the dynamic behavior of natural tissues. Current spatiotemporal biomaterial functionalization approaches are based on cytotoxic, technically challenging, or non-scalable chemistries, which has hampered their widespread

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持